{"id":11,"date":"2016-11-12T18:22:35","date_gmt":"2016-11-12T18:22:35","guid":{"rendered":"http:\/\/labs.icahn.mssm.edu\/giannarellilab\/?page_id=11"},"modified":"2019-10-08T18:29:31","modified_gmt":"2019-10-08T18:29:31","slug":"projects-and-grants","status":"publish","type":"page","link":"https:\/\/labs.icahn.mssm.edu\/giannarellilab\/projects-and-grants\/","title":{"rendered":"Projects and Grants"},"content":{"rendered":"

[et_pb_section fb_built=”1″ fullwidth=”on” _builder_version=”3.19.10″][et_pb_fullwidth_header title=”Projects and Grants” admin_label=”Projects and Grants” _builder_version=”3.19.10″ background_color=”#00c1fc”][\/et_pb_fullwidth_header][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”3.0.47″][et_pb_row _builder_version=”3.0.48″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.0.47″ parallax=”off” parallax_method=”on”][et_pb_text _builder_version=”3.19.10″ text_font=”||||||||” text_font_size=”15px” background_size=”initial” background_position=”top_left” background_repeat=”repeat”]<\/p>\n

 <\/p>\n

DISSECTING THE CELLULAR AND MOLECULAR IMMUNE INTERACTIONS IN HUMAN ATHEROSCLEROSIS<\/p>\n

We use a multi-tissue, systems biology approach to infer arterial wall- and blood-specific immune networks that govern the immune response at different stages of human atherosclerosis. The use of systems biology that integrate cutting-edge technologies like CyTOF mass-cytometry,\u00a0RNA-seq, CITE-Seq and shot-gun proteomics to measure immune cell variation in human samples will deepen our knowledge of the contribution of the immune system to cardiovascular and set the stage to the selection of molecular targets for novel anti-inflammatory therapies.<\/p>\n

 <\/p>\n

DRUG REPURPOSING: We are currently working on two projects.<\/p>\n

SINGLE-CELL-DRIVEN DRUG REPOSITIONING APPROACHES TO TARGET INFLAMMATION IN ATHEROSCLEROSIS<\/p>\n

The goal of this study is to rigorously validate the pre-clinical efficacy of phase 2a-ready test compound identified using systems biology and computational drug repurposing analyses with the goal of translating the findings into human clinical trial.<\/p>\n

 <\/p>\n

\"FiguresNETWORK-DRIVEN DRUG REPURPOSING APPROACHES TO TREAT CORONARY ARTERY DISEASE<\/p>\n

Systems genetics is a new approach that models molecular dysfunctions of complex traits like CAD in the form of regulatory gene networks (RGNs). Combined with network-driven computational approaches to re-purpose existing drugs targeting networks in complex diseases, systems genetics can speed up the discovery of powerful strategies to treat CAD. We are rigorously validating the pre-clinical efficacy of either FDA approved or phase 2a-ready test compound(s), with the goal of translating the findings into human clinical trials. We use translational non-invasive imaging modalities to measure the efficacy of candidate compounds targeting RGNs in large animal models of atherosclerosis for the translation of our findings to clinical trials.<\/p>\n

 <\/p>\n

 <\/p>\n

 <\/p>\n

UNDERSTANDING CORONARY ARTERY DISEASE (CAD GENOMICS)<\/p>\n

The goal is to use the GWAS results as a starting point, together with evidence at the molecular, cellular, and tissue level, to examine the underlying functional biology of the cardiovascular disease pathways in which they are involved. Junior scientists work alongside experienced investigators in each participating institution, promoting further research in this exciting and fast-moving field.<\/p>\n

 <\/p>\n

ROLE OF ANGIOGENESIS IN ATHEROSCLEROSIS<\/p>\n

This project outlines a novel paradigm of atherosclerosis as an angiogenic-dependent disease in which neovascularization of plaque is intimately involved. Elucidating the role pro-angiogenic factors and identifying novel pathway(s) relevant for neovascularization in human atherosclerotic disease could yield the discovery of novel biomarkers and therapeutic targets of plaque instability leading to clinical events.<\/p>\n

 <\/p>\n

 <\/p>\n

GRANTS<\/p>\n

R03HL135289 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <\/p>\n

NIH-NHLBI<\/p>\n

PI: Chiara Giannarelli<\/p>\n

 <\/p>\n

UH2 TR002067-01\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <\/p>\n

NIH\/NCATS<\/p>\n

 <\/p>\n

R21TR001739\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <\/p>\n

MPI: Chiara Giannarelli (contact); Johan Bjorkegren<\/p>\n

 <\/p>\n

LEDUCQ Transatlantic networks of Excellence Program\u00a0\u00a0 <\/p>\n

Sinai PI: Bjorkegren, Schadt; MPI: Schunkert-Lusis.\u00a0 Giannarelli: co-Investigator<\/p>\n

 <\/p>\n

K23HL111339 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <\/p>\n

NIH-NHLBI<\/p>\n

PI: Chiara Giannarelli<\/p>\n

 <\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"

  DISSECTING THE CELLULAR AND MOLECULAR IMMUNE INTERACTIONS IN HUMAN ATHEROSCLEROSIS We use a multi-tissue, systems biology approach to infer arterial wall- and blood-specific immune networks that govern the immune response at different stages of human atherosclerosis. The use of systems biology that integrate cutting-edge technologies like CyTOF mass-cytometry,\u00a0RNA-seq, CITE-Seq and shot-gun proteomics to measure […]<\/p>\n","protected":false},"author":200,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"

R03HL135289 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (09\/15\/2016-08\/31\/2018)<\/p>

NIH-NHLBI<\/p>

PI: Chiara Giannarelli<\/p>

DISSECTING THE CELLULAR AND MOLECULAR IMMUNE INTERACTIONS IN HUMAN ATHEROSCLEROSIS<\/p>

We use a mult \"Phospho_viSNE.pptx\"i-tissue, systems biology approach to infer arterial wall- and blood-specific immune networks that govern the immune response at different stages of human atherosclerosis. The use of systems biology that integrate cutting-edge technologies like CyTOF mass-cytometry,\u00a0 RNA-seq and shot-gun proteomics to measure immune cell variation in human samples will deepen our knowledge of the contribution of the immune system to cardiovascular and set the stage to the selection of molecular targets for novel anti-inflammatory therapies.<\/p>

\u00a0<\/p>

\u00a0<\/p>

\u00a0<\/p>

\u00a0<\/p>

UH2 TR002067-01\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (07\/01\/2017-06\/30\/2020)<\/p>

NIH\/NCATS<\/p>

Single-cell-driven drug repositioning approaches to target inflammation in atherosclerosis<\/p>

The goal is to rigorously validate the pre-clinical efficacy of phase 2a-ready test compound identified using systems biology and computational drug repurposing analyses with the goal of translating the findings into human clinical trial (UH3 phase, clinical trial planning).<\/p>

Role: PI<\/p>

\u00a0<\/p>

R21TR001739\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (09\/01\/2016-08\/31\/2018)<\/p>

NETWORK-DRIVEN DRUG REPURPOSING APPROACHES TO TREAT CORONARY ARTERY DISEASE<\/p>

MPI: Chiara Giannarelli (contact); Johan Bjorkegren.<\/p>

\"FiguresSystems genetics is a new approach that models molecular dysfunctions of complex traits like CAD in the form of regulatory gene networks (RGNs). Combined with network-driven computational approaches to repurpose existing drugs targeting networks in complex diseases, systems genetics can speed up the discovery of powerful strategies to treat CAD. We are rigorously validating the pre-clinical efficacy of either FDA approved or phase 2a-ready test compound(s), with the goal of translating the findings into human clinical trials. We use translational non-invasive imaging modalities to measure the efficacy of candidate compounds targeting RGNs in large animal models of atherosclerosis for the translation of our findings to clinical trials.<\/p>

\u00a0<\/p>

\u00a0<\/p>

\u00a0<\/p>

K23HL111339 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (09\/01\/2013-05\/31\/2018)<\/p>

NIH-NHLBI<\/p>

PI: Chiara Giannarelli<\/p>

ROLE OF ALTERNATIVELY SPLICED TISSUE FACTOR IN ATHEROSCLEROSIS<\/p>

This project outlines a novel paradigm of atherosclerosis as an angiogenic-dependent disease in which neovascularization of plaque is intimately involved. Elucidating the role of asTF as novel pro-angiogenic factor and identifying novel pathway(s) relevant for neovascularization in human atherosclerotic disease could yield the discovery of novel biomarkers and therapeutic targets of plaque instability leading to clinical events.<\/p>

\u00a0<\/p>

LEDUCQ Transatlantic networks of Excellence\u00a0\u00a0 (01\/01\/2014-12\/31\/2017)<\/p>

Fondation Leducq<\/p>

Sinai PI:Bjorkegren, Schadt; MPI: Schunkert-Lusis.\u00a0 Giannarelli: co-Investigator<\/p>

UNDERSTANDING CORONARY ARTERY DISEASE (CAD GENOMICS)<\/p>

The goal is to use the GWAS results as a starting point, together with evidence at the molecular, cellular, and tissue level, to examine the underlying functional biology of the cardiovascular disease pathways in which they are involved. Junior scientists work alongside experienced investigators in each participating institution, promoting further research in this exciting and fast-moving field.<\/p>

\u00a0<\/p>

16SDG27250090 Scientist Development Grant\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (01\/01\/2016-12\/31\/2018)<\/p>

AHA Founders Affiliates<\/p>

PI: Claudia Calcagno; Giannarelli: co-investigator<\/p>

Quantitative permeability imaging of the mouse atherosclerotic vessel wall by self-gated DCE-MRI with compressed sensing<\/p>

The goal of this grant is to develop of a self-gated dynamic contrast enhanced (DCE) MRI with compressed sensing acceleration to quantify permeability in the aortic root of atherosclerotic mice.<\/p>

\u00a0<\/p>","_et_gb_content_width":"","footnotes":""},"class_list":["post-11","page","type-page","status-publish","hentry"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/labs.icahn.mssm.edu\/giannarellilab\/wp-json\/wp\/v2\/pages\/11","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/labs.icahn.mssm.edu\/giannarellilab\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/labs.icahn.mssm.edu\/giannarellilab\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/labs.icahn.mssm.edu\/giannarellilab\/wp-json\/wp\/v2\/users\/200"}],"replies":[{"embeddable":true,"href":"https:\/\/labs.icahn.mssm.edu\/giannarellilab\/wp-json\/wp\/v2\/comments?post=11"}],"version-history":[{"count":18,"href":"https:\/\/labs.icahn.mssm.edu\/giannarellilab\/wp-json\/wp\/v2\/pages\/11\/revisions"}],"predecessor-version":[{"id":611,"href":"https:\/\/labs.icahn.mssm.edu\/giannarellilab\/wp-json\/wp\/v2\/pages\/11\/revisions\/611"}],"wp:attachment":[{"href":"https:\/\/labs.icahn.mssm.edu\/giannarellilab\/wp-json\/wp\/v2\/media?parent=11"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}